Latest Articles

Publication Date
All News Scientific
Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea - Moneycontrol

Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea Moneycontrol

Published: Oct. 30, 2025, 8:35 a.m.
Read Full Article
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - MSN

ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability MSN

Published: Oct. 30, 2025, 4:04 a.m.
Read Full Article
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging - springermedicine.com

Insights into endometrial cancer management: a comprehensive guide through multimodality imaging springermedicine.com

Published: Oct. 29, 2025, 10:52 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace

Published: Oct. 28, 2025, 5:03 a.m.
Read Full Article
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 11:43 p.m.
Read Full Article
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 10:53 p.m.
Read Full Article
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks

Published: Oct. 27, 2025, 10:21 p.m.
Read Full Article
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!